UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of April 2026
Commission
File Number 001-15170
GSK plc
(Translation
of registrant's name into English)
79 New Oxford Street, London, WC1A 1DG
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
Issued: 27 April 2026, London UK
TESARO, a GSK subsidiary, provides update on AnaptysBio, Inc.
litigation
GSK plc (LSE/NYSE: GSK) subsidiary, TESARO, Inc., confirms that the
Delaware Chancery Court has granted the motion to dismiss filed by
AnaptysBio, Inc. against TESARO's claim for anticipatory breach.
The court's ruling does not address the merits of the principal
contractual dispute between the parties and has no impact on
TESARO's remaining claim against AnaptysBio for declaratory
judgment. GSK
and TESARO are
firmly of the view that these allegations are entirely without
merit and remain focused on
pursuing that claim at trial.
TESARO initiated this litigation following allegations made by
AnaptysBio that TESARO has not fulfilled certain requirements of
the license agreement entered in March 2014 between the parties and
that AnaptysBio intends to revoke TESARO's licence for
dostarlimab.
Jemperli, which is the brand
name for dostarlimab, is currently approved in over 35 countries
for use in certain endometrial cancers, the most common
gynaecologic cancer in the United States. GSK and TESARO have
reported significant growth for Jemperli driven by label expansions
in endometrial cancer, including in the US and EU. A robust and
ambitious clinical trial programme to evaluate the potential use of
dostarlimab in additional cancers, including rectal, colon and head
and neck, is ongoing.
About GSK
GSK is a global biopharma company with a purpose to unite science,
technology, and talent to get ahead of disease together. Find out
more at www.gsk.com.
|
GSK enquiries
|
|
|
|
|
Media:
|
Tim Foley
|
+44 (0) 20 8047 5502
|
(London)
|
|
|
Madison Goring
|
+44 (0) 20 8047 5502
|
(London)
|
|
|
Kathleen Quinn
|
+1 202 603 5003
|
(Washington DC)
|
|
|
Alison Hunt
|
+1 540 742 3391
|
(Washington DC)
|
|
|
|
|
|
|
Investor Relations:
|
Constantin Fest
|
+44 (0) 7831 826525
|
(London)
|
|
|
James Dodwell
|
+44 (0) 20 8047 2406
|
(London)
|
|
|
Mick Readey
|
+44 (0) 7990 339653
|
(London)
|
|
|
Steph Mountifield
|
+44 (0) 7796 707505
|
(London)
|
|
|
Sam Piper
|
+44 (0) 7824 525779
|
(London)
|
|
|
Jeff McLaughlin
|
+1 215 751 7002
|
(Philadelphia)
|
|
|
Frannie DeFranco
|
+1 215 751 3126
|
(Philadelphia)
|
|
|
|
|
|
Cautionary statement regarding forward-looking
statements
GSK cautions investors that any forward-looking statements or
projections made by GSK, including those made in this announcement,
are subject to risks and uncertainties that may cause actual
results to differ materially from those projected. Such factors
include, but are not limited to, those described in the "Risk
Factors" section in GSK's Annual Report on Form 20-F for
2025.
Registered in England & Wales:
No.
3888792
Registered Office:
79
New Oxford Street
London
WC1A
1DG
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
|
GSK plc
|
|
|
(Registrant)
|
|
|
|
|
Date: April
27, 2026
|
|
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GSK plc
|